ttfields for lung cancer - how does it actually work and is it different for meso

That's really helpful context. I've been digging into the ttfields data myself since my oncologist mentioned it as a possible adjunct to HIPEC, and you're right that the lung cancer evidence is way more robust than what we have for peritoneal meso. The FDA approval came through in 2015 for glioblastoma first, then expanded to NSCLC, but peritoneal is still pretty much in the research phase.

I pulled some of the KEYNOTE-407 data and the response rates for lung cancer are solid, but I keep running into the same wall you did. The trials that include peritoneal meso are limited and they're usually combining it with chemotherapy in specific protocols. My surgical oncologist at Cleveland Clinic said the electrical field behavior is different when you're dealing with abdominal cavity tumors versus pleural, which makes sense anatomically but it also means the electrode placement and dosing might need tweaking.

I'm actually asking my team about trial eligibility in January when I get my post-diagnostic scans done. They're evaluating me for HIPEC surgery and I want to know if ttfields could be part of the sequencing afterward. The timing question you mentioned is exactly what I'm trying to figure out. Right now I'm in this evaluation phase and I'm documenting everything in my symptom journal so I can speak specifically about my performance status when we talk about what's actually feasible.

Did your oncologist say whether they'd revisit it later, or was it more of a flat no?

Thanks for breaking this down. I've been reading through the NCCDC data on ttfields and peritoneal meso is even further behind on the evidence curve than pleural, which is frustrating because I'm actively looking at whether it could complement HIPEC. My oncologist at Cleveland Clinic mentioned it in passing back in December but couldn't point me to any completed trials specific to peritoneal cases.

The mechanism you described is accurate from what I've found in the literature. Tumor Treating Fields disrupt mitotic spindle formation during cell division, so theoretically it should work on meso cells the same way it does on lung cancer cells. But there's a critical difference in how the fields are delivered. For lung cancer the electrode placement is relatively straightforward. With peritoneal meso you're dealing with a much larger abdominal cavity and multiple visceral surfaces, which changes the field distribution significantly. I actually emailed a researcher at Memorial Sloan Kettering in early January asking about this and they confirmed they're only recruiting for pleural cases at the moment.

The performance status thing you mentioned is key. I'm keeping detailed notes on my symptom progression (my journal shows stable CA-125 markers since November) specifically because if a trial opens up for peritoneal cases I want to be in the best position to qualify. Timing really does matter.

What stage were you at when they said you weren't a fit? I'm trying to understand if there's a window where ttfields makes sense to layer in alongside other treatments.

That's a really solid breakdown. My dad's oncologist at Northwestern actually brought up ttfields during one of our palliative care consults back in September, so I've done a lot of reading on this since then.

You're right that the evidence is way thinner for pleural meso compared to NSCLC. The lung cancer trials have thousands of patients at this point. For meso we're talking maybe a handful of small studies, and honestly the response rates aren't as clear. The mechanism makes theoretical sense (disrupting mitotic spindle formation in rapidly dividing cells) but mesothelioma grows differently than adenocarcinoma. It's more aggressive, more diffuse along the pleura, and by the time most people get diagnosed it's already stage III or IV like my dad.

What I found helpful was asking his oncologist point blank: would this extend his life or improve quality of life, or is it mainly something that might buy us time for other therapies? Because that changes everything. In my dad's case at stage IV with his performance status declining, the answer was it wouldn't change his prognosis enough to justify wearing the device full time. The electrode pads are bulky, they heat up, skin irritation is common. For someone already dealing with pleural effusions and pain, that felt like adding burden for minimal upside.

The clinical trial piece is huge too. If you're being considered, ask what the actual endpoints are. Are they measuring survival? Progression-free survival? Symptom control? Different trials measure different things.

Your buddy should definitely ask his doc but also ask to see the actual study data, not just the marketing summary. Makes a difference.

yeah my mom's oncologist mentioned this too and i was like wait is this actually proven for meso or are we just throwing everything at the wall, so thanks for breaking it down like this. def gonna ask more questions at her next appointment.

I've been tracking the TTFields literature pretty closely since my diagnosis came through in November, so this is helpful context. My oncologist at Cleveland Clinic mentioned it as a possibility but hasn't pushed it hard, which honestly made me want to dig deeper into why.

The distinction you're making between pleural and peritoneal is crucial. I have peritoneal meso and when I looked at the actual trial data, most of what's being studied right now is either pleural cases or non-small cell lung like you mentioned. There's one phase 2 study running specifically for peritoneal but enrollment is slow and the inclusion criteria are pretty restrictive. You have to be post-HIPEC ideally, stable disease, good functional status. That's a narrow window.

What got me was reading through the mechanism papers. TTFields work by disrupting mitotic spindle formation, which is elegant in theory but the electric field penetration through abdominal tissue is different than thoracic. The impedance is higher. So even if it works for lung cancer, the physics might not translate perfectly to what's happening in my peritoneal cavity.

I asked my surgeon point blank in December whether he'd seen any data suggesting TTFields improved outcomes in peritoneal cases specifically and he basically said the evidence isn't there yet. He didn't say no, he said show me the data first. That's become my threshold too.

If you're considering it, I'd want to see response rates from cases that match your stage and histology exactly, not just general TTFields efficacy for meso. Your instinct about asking straight up what the evidence shows is spot on. Don't let anyone sell you a tool because it exists.